Fast Five Quiz: Precision Medicine and Genetic Testing for Colorectal Cancer

Testing for microsatellite instability and mismatch repair provides needed information for the use of pembrolizumab, a programmed death 1 inhibitor, as demonstrated by Le and colleagues and Zhao et al. Pembrolizumab was first granted accelerated approval from the US Food and Drug Administration in May 2017 for unresectable or metastatic microsatellite instability-high or deficient mismatch repair colon cancer following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan. In 2020, it was also approved for first-line use in that patient population on the basis of results from the KEYNOTE-177 trial.

Learn more about precision medicine for metastatic CRC.

Medscape © 2022 WebMD, LLC

Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.

Cite this: Ali Alqahtani. Fast Five Quiz: Precision Medicine and Genetic Testing for Colorectal Cancer - Medscape - Jun 17, 2022.